USPTO trademark

GENLINK3D

RegisteredUSPTOWord markClass 9Class 35Class 42

"GENLINK3D" is a word mark owned by Enhanced Genomics, filed at the USPTO on November 25, 2022. It is registered and covers classes 9, 35 and 42.

Get this data via the API
Official USPTO record
GENLINK3D trademark as filed
As filed with the USPTO
Status
Registered
Since August 19, 2025
Filed
November 25, 2022
Registered
August 19, 2025
Expires
Not recorded
Application no.
97691779
Registration no.
7895843
Office
USPTO
United States Patent and Trademark Office
Mark type
Word mark
3 classes
Ownership

Who owns GENLINK3D

The owner and representative on file with the office.

Owner

Enhanced Genomics

Cambridge, United Kingdom

Representative

Emily M. Chilson

Andrus Intellectual Property Law, LLP

Goods and services

What the mark covers

The products and services GENLINK3D is filed for, grouped by Nice class.

  • Downloadable software for profiling three-dimensional genome folding at high resolution for all genes and their enhancers; Downloadable software for visualisation, analysis, and manipulation of biological molecules in the field of genomics; Downloadable software for visualisation, analysis, and manipulation of biological molecules; Downloadable software for modelling and prediction of biological interactions; Downloadable software for genome sequencing; Scientific research apparatus and instruments being laboratory devices for detecting genetic sequences by profiling three-dimensional genome folding at high resolution for all genes and their enhancers; Electronic database in the field of genomics recorded on computer media; Downloadable educational publications, namely, printable workbooks, booklets, scientific journals, and articles in the field of genomics; Downloadable electronic publications in the nature of scientific journals and articles in the field of drug discovery; Downloadable electronic publications in the nature of scientific journals and articles in the field of medical diagnosis; Downloadable electronic publications in the nature of scientific journals and articles in the field of biomarker discovery; Downloadable electronic publications in the nature of scientific journals and articles in the field of genomics; Downloadable electronic publications in the nature of scientific journals and articles in the field of bioinformatics

  • Business data analysis in the field of drug discovery; Business data analysis in the field of medical diagnosis; Business data analysis in the field of biomarker discovery; Business data analysis in the field of genomics; Business data analysis in the field of bioinformatics; Data processing in the field of drug discovery; Data processing in the field of medical diagnosis; Data processing in the field of biomarker discovery; Data processing in the field of genomics; Data processing in the field of bioinformatics; Database management; Database management and statistical reporting services for business purposes; Business information services in the fields of medical diagnosis, biomarker discovery, genomics, and bioinformatics; Business consulting services in the fields of medical diagnosis, biomarker discovery, genomics, and bioinformatics; Business consulting services in the field of drug discovery; Business consulting services in the field of biomarker discovery; Market intelligence services in the fields of medical diagnosis, biomarker discovery, genomics, and bioinformatics; Electronic data collection and data submission services for business purposes in the fields of medicine and healthcare; Business advisory services, consultancy and information

  • Software as a service (SAAS) services featuring software for profiling three-dimensional genome folding at high resolution for all genes and their enhancers; Software as a service (SAAS) services featuring software for analyzing biological data for research and development of drugs in the field of genomics; Software as a service (SAAS) services featuring software for diagnosis of genetic diseases by analyzing biological data; Software as a service (SAAS) services featuring software for development of biomarkers for medical treatment; Software as a service (SAAS) services featuring software for collection, analysis and interpretation of biological data; Software as a service (SaaS) services featuring software for visualisation, analysis, and manipulation of biological molecules; Software as a service (SaaS) services featuring software for modelling and prediction of biological interactions; Software as a service (SaaS) services featuring software for genome sequencing; Software as a service (SAAS) services featuring software for data analysis, data processing and database management in the field of genomics; Software as a service (SAAS) services featuring software for data analysis for research and development of artificial intelligence and machine learning in the field of genomics; Platform as a service (PAAS) featuring computer software platforms for data analysis, data processing and database management in the field of genomics; Platform as a service (PAAS) featuring computer software platforms for analyzing biological data for research and development of drugs in the field of genomics; Platform as a service (PAAS) featuring computer software platforms for diagnosis of genetic diseases by collecting and analyzing biological data; Platform as a service (PAAS) featuring computer software platforms for development of biomarkers for medical treatment; Platform as a service (PAAS) featuring computer software platforms for profiling three-dimensional genome folding at high resolution for all genes and their enhancers; Platform as a service (PAAS) featuring computer software platforms for collection, analysis and interpretation of biological data; Platform as a service (PaaS) featuring computer software platforms for visualisation, analysis, and manipulation of biological molecules; Platform as a service (PaaS) featuring computer software platforms for modelling and prediction of biological interactions; Platform as a service (PaaS) featuring computer software platforms for genome sequencing; Platform as a service (PaaS) featuring computer software platforms for performing data analysis, data processing, and database management in the fields of medical diagnosis, biomarker discovery, genomics, and bioinformatics; Platform as a service (PaaS) featuring computer software platforms using artificial intelligence for machine learning in the field of genomics; Design and development of software for profiling three-dimensional genome folding at high resolution for all genes and their enhancers; Design and development of computer software in the field of data analysis for drug discovery; Design and development of computer software in the field of data analysis for medical diagnosis; Design and development of computer software in the field of collection and analysis of biological data for biomarker discovery; Design and development of computer software in the field of genomic analysis; Design and development of computer software in the field of bioinformatic analysis; Design and development of computer software for visualisation, analysis, and manipulation of biological molecules; Design and development of computer software for modelling and prediction of biological interactions; Design and development of computer software for genome sequencing; Design and development of computer software for performing data analysis in the fields of medical diagnosis, biomarker discovery, genomics, and bioinformatics; Design and development of computer software using artificial intelligence for machine learning in the field of genomics; Scientific research services for others in the field of genomics; Scientific research services for others in the field of drug discovery; Scientific research services for others in the field of medical diagnosis; Scientific research services for others in the field of biomarker discovery; Scientific research services for others in the field of bioinformatics; Scientific research consulting services in the field of drug discovery; Scientific research consulting services in the field of medical diagnosis; Scientific research consulting services in the field of biomarker discovery; Scientific research consulting services in the field of genomics; Scientific research consulting services in the field of bioinformatics; Scientific and technological services, namely, scientific research and analysis featuring profiling three-dimensional genome folding at high resolution for all genes and their enhancers, in the field of genomics; Scientific and technological services, namely, scientific testing in the field of drug discovery; Scientific and technological services, namely, scientific testing in the field of medical diagnosis; Scientific and technological services, namely, scientific testing in the field of biomarker discovery; Scientific and technological services, namely, scientific testing in the field of genomics; Scientific and technological services, namely, scientific testing in the field of bioinformatics; Computer programming services for scientific data processing; Providing temporary use of on-line non-downloadable software for profiling three-dimensional genome folding at high resolution for all genes and their enhancers; Compiling data for research purposes in the field of medical science; Advisory services relating to computer software design for genomic analysis; Consultancy in the field of software design for genomic analysis; Providing information in the field of scientific research in the field of genomics; Compiling data for scientific research purposes in the field of medical science

History

What has happened so far

Steps recorded by the USPTO, newest first.

  1. Automatic update of assignment of ownership
  2. Notice of registration confirmation emailed
  3. Registered-principal register
  4. Official gazette publication confirmation e-mailed
  5. Published for opposition
  6. Notification of notice of publication e-mailed
  7. Approved for pub - principal register
  8. Teas/email correspondence entered
  9. Correspondence received in law office
  10. Teas response to office action received

10 earlier steps on the official record.

FAQ

About GENLINK3D

Who owns the trademark "GENLINK3D"?

The USPTO trademark "GENLINK3D" (application 97691779) is owned by Enhanced Genomics.

What is the status of "GENLINK3D"?

Its status at the USPTO is: registered.

When was "GENLINK3D" registered?

It was registered on August 19, 2025.

API

Get this data via the API

Everything on this page comes from the Signa API. Pull GENLINK3D and marks like it into your own product with one request.

  • GET/v1/trademarks/{id}

    The full record: owners, classes, dates and images

  • GET/v1/trademarks/{id}/events

    Every step in the office history

  • GET/v1/proceedings?trademark_id={id}

    Oppositions and cancellations against the mark

Get API keyView docs
GET /v1/trademarks/{id}
ID=tm_019d2b24-a57e-7219-8fde-087beb033c03
curl https://api.signa.so/v1/trademarks/$ID \
  -H "Authorization: Bearer $SIGNA_API_KEY"
Response
{
  "id": "tm_019d2b24-a57e-7219-8fde-087beb033c03",
  "object": "trademark",
  "mark_text": "GENLINK3D",
  "status": {
    "primary": "active",
    "stage": "registered"
  },
  "office_code": "US",
  "application_number": "97691779",
  "filing_date": "2022-11-25",
  "nice_classes": [
    9,
    35,
    42
  ],
  "owners": [
    {
      "name": "ENHANCED GENOMICS",
      "entity_id": null
    }
  ]
}